Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology

bullseye, take aim

Founded in 2020, Scorpion is agnostic about the potential therapies and targets it will explore with what it describes as its drug-hunting engine. But the company is hoping to unveil its first drug candidate this year.

Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies

Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies

What You Should Know:

– Mission Bio launches industry’s first and only
single-cell multi-omics platform, is announcing the launch of its most
comprehensive instrument to-date, to save the industry billions of dollars in
drug development costs and bring life-saving treatments to market at least six months

– Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that drive disease to enable faster, more successful development of precision cancer therapies.

– Spun out of the lab at UCSF and since led by a former
Berkeley engineer, the company has caught the attention of strategic investors
like Mayfield and Agilent, who see it as one to rival 10x Genomics.

Mission Bio, Inc., a South San Francisco, CA-based
company announced the launch of a complete Tapestri® Single-cell Multi-omics
Solution, the most comprehensive single-cell multi-omics platform on the
market. With a new instrument, single-cell
multi-omics reagent kits, TotalSeq-D™ antibody content from BioLegend, and
visualization software, the complete package provides layered insight into
multiple analytes across all blood cancers, reducing drug development time and cost by at least half.
The company is partnering with BioLegend, a global leader and provider of
world-class, cutting-edge antibodies and reagents, to develop antibody panels
for single-cell protein detection with the new device.

Single Cell for DNA and Protein?

complexity of cancer cannot be overcome without
comprehensive tools. Running a large-scale clinical study costs around $40
million, and the pharmaceutical industry is losing $50 billion a year on failed
clinical trials and ineffective drugs. It is essential to identify precision
biomarkers and characterize resistance mechanisms — both DNA mutations and
protein expression– to minimize losses, maximize treatment efficacy, and
accelerate time to market.

our technology, you can unlock the ground truth of cancer:
our DNA-Protein kit offers, for the first time, the
ability to understand the communication pathway all the way from the blueprint
of life in the center of the cell — DNA — to the exterior of the cell via
surface proteins, without inference or conjecture,” explained Nigel Beard,
Ph.D., Chief Technology Officer and SVP of Operations of Mission Bio. “It’s a product builders’ dream to deliver a disruptive
technology that truly empowers our customers with the potential to unravel the
many connected threads that make up the complexity of cancer.”

Uniquely Detect DNA & Protein Simultaneously from the Same Cell

Mission Bio’s new solution
can uniquely detect DNA and protein simultaneously from the same cell and is
already adopted by marquee NCI Cancer Centers,
including MD Anderson Cancer Center, Memorial
Sloan Kettering Cancer Center, University of
Texas, Southwestern Medical Center, and the University of California, San
Francisco. The offering sets a new standard for
comprehensive single-cell multi-omics, providing:

2x Faster Analysis – The new Tapestri
Instrument uniquely enables a simpler workflow for faster time-to-data.
By integrating both genotype and phenotype data on a single Tapestri run,
researchers save weeks in processing and analysis time in
running a single multi-omics workflow.

Get More Out of Your Sample – Save precious
samples by utilizing new reagent kits for a single
workflow to obtain both mutation data and protein expression.

– New Tapestri Cell Protein Staining Reagent Kits from Mission Bio are optimized with a fully developed protocol and compatible with new TotalSeq-D kits from BioLegend and existing Tapestri Core Reagent Kits.

– The 45-plex TotalSeq-D Heme Oncology Cocktail is the first catalog panel in partnership with BioLegend for single-cell surface protein detection with the Tapestri Platform. The panel is pre-mixed, titrated, and lyophilized and consists of antibodies applicable to various hematological malignancies.

Visualization Tools for
Integrated Insights
 – From novice users to savvier bioinformaticians, the
updated Tapestri Pipeline and Insights software provide publication-ready
visualization tools that make it easier to understand data — from raw
sequencing files to multi-dimensional cluster plots.

“The value of connecting the mutations in single-cells with their immunophenotypes directly has been a game-changer in allowing us to discover cell surface markers that identify disease stem cells. Merging multiple assays saves us a tremendous amount of time and allows for better insights into disease biology so that we can develop more precise and effective therapies,” said Stephen Chung, M.D., University of Texas, Southwestern Medical Center.

CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform

CancerIQ Raises $5M to Expand Genetic Cancer Risk Assessment Platform

What You Should Know:

– CancerIQ raises $5M in Series A funding led by HealthXVentures to accelerate the growth of its genetic cancer risk assessment platform to identify and manage patients at high risk of cancer.

– CancerIQ’s technology enables hospitals to use genomics
to personalize the prevention and early detection of cancer.

– Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading EMRs.

CancerIQ, an
enterprise precision health platform for cancer, today announced it has raised
$4.8M in Series A funding led by HealthX
, a digital
venture capital firm led by Mark Bakken, the founder and
former CEO of Nordic Consulting, the
largest Epic consulting firm. CancerIQ will use the funding to accelerate the
growth of its current offering and deepen integrations with EHRs and genetic
testing partners. Other institutional investors including Impact Engine and
Lightbank, co-founded by Eric Lefkofsky (founder of Tempus and co-founder of
Groupon) and Brad Keywell (co-founder of Groupon), also participated in the

Genetic Cancer Risk Assessment Platform to Manage
Patients at High Risk of Cancer

Founded in 2013, CancerIQ helps healthcare providers use genetic information to predict, preempt, and prevent cancer across populations in both urban and rural settings. By analyzing family history, running predictive risk models, and automating NCCN guidelines, CancerIQ empowers providers with the genetic expertise to prevent cancer or catch it early.

CancerIQ’s workflows enable health systems to execute
precision health strategies for patients predisposed to cancer, by:

• Identifying the 25 percent of the patient population that
qualifies for genetic testing

• Streamlining the genetic testing and counseling process,
via telehealth if required

• Managing high-risk patients over time

• Tracking outcomes at the individual and population levels

In addition, the platform allows hospitals to convert their
cancer risk assessment and management programs to virtual visits with its
complete telehealth cancer risk platform. CancerIQ has been rapidly adopted by
some of the top health systems in the country and fully integrates with
genetics laboratories, EHRs, and specialty software vendors to streamline
workflow, guide clinician decision making, achieve cost savings, and — most
importantly — improve patient outcomes.

Recent Traction/Milestones

CancerIQ will use the funding to accelerate the growth of
its current offering and deepen integrations with EHRs and genetic testing
partners. The company is experiencing a rapid growth year despite the COVID-19
crisis. Precision health has become an even more important technique for early
detection and prevention of disease. Over 80,000 patients have missed their
cancer screening appointments, but health systems are rapidly adopting CancerIQ
to triage and prioritize those in need of most urgent care.

“Partnering with HealthX allows us to build on the solid foundation we have serving over 70 institutions, and enable system-wide precision health,” said Feyi Ayodele, CEO, CancerIQ.

Addition of Strategic Hires to Epic Integration Team

Two new hires recently joined CancerIQ’s newly formed
Integrated Products team from Epic, with the goal of advancing CancerIQ’s
integration with leading EMRs:

Lisa Glaspie, Director of Integrated Products

– Glaspie spent 16 years at Epic, where she was directly involved in many integrations, data management, and conversion projects spanning a wide array of clinical and specialty system vendors, as well as custom in-house products. She will inform how CancerIQ can be deeply integrated across more clinical specialties.

Ashar Wasi, Integrated Product Specialist

– Wasi spent the last 11 years at Epic on the implementation
team for Epic’s radiology and cardiology modules. At CancerIQ, he will help
client teams understand different integration methods and provide context on
the scalability of CancerIQ’s FHIR-based approach.

“To engage primary care, radiology, and cardiology in precision health — we need our content to be deeply embedded in the EHR systems they already use. We’re excited to bring Lisa and Ashar on board for their domain expertise with Epic, so fewer high risk patients fall through the cracks,” added Ayodele.